A new flurry of drug deals shows how the global pharmaceutical industry is reversing course as companies narrow their focus after decades of diversifying their drug portfolios Swiss drug giant Novartis AG and the UKs GlaxoSmithKline PLC on Tuesday were the latest to illustrate that aboutface announcing more than  billion in deals Novartis will sell its animaldrugs business to Eli Lilly  Co and most of its vaccine business to Glaxo and Novartis will buy a portfolio of cancer therapies from Glaxo